GUBamy: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข2 clinical studies cited
- โขOverall evidence level: low
- โข7 research gaps identified
Research Studies
Gubra Announces Positive GUBamy Phase 1 SAD Data
Gubra A/S (2024) โข Company press release
Phase 1 single ascending dose study in healthy volunteers evaluating safety, pharmacokinetics, and preliminary weight effects of GUBamy. Demonstrated dose-proportional PK, 11-day half-life, and dose-dependent weight loss.
Key Findings
- Half-life of 270 hours (11 days) confirmed
- Dose-proportional pharmacokinetics across all doses
- Approximately 3% weight loss in highest dose groups (3.5-6.0 mg) over 6 weeks
- Placebo group: approximately +1% weight change
- Well tolerated with predominantly mild GI adverse events
Limitations: Single-dose study in healthy volunteers; small sample sizes per cohort; company press release without peer-reviewed publication; 6-week observation period
Gubra Announces Positive GUBamy Phase 1 Interim MAD Results
Gubra A/S (2024) โข Company press release
Interim results from the multiple ascending dose cohort of the phase 1 study evaluating 2 mg weekly subcutaneous GUBamy in healthy volunteers. Demonstrated substantial weight loss by day 43.
Key Findings
- LS mean weight loss of -7.77% at day 43 with GUBamy 2 mg weekly
- Placebo group showed +1.99% weight change at day 43
- Well tolerated with predominantly mild GI adverse events
- Consistent with SAD study safety profile
Limitations: Interim data from a single MAD cohort; company press release; small sample size; short duration (43 days); healthy volunteers rather than obese patients
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
0View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขPeer-reviewed publication of phase 1 data
- โขPhase 2 dose-ranging study in obese patients
- โขLonger-term efficacy and safety data (26-52 weeks)
- โขCombination studies with GLP-1 RAs (the key commercial value proposition)
- โขHead-to-head comparison with cagrilintide and petrelintide
- โขEffect on glycemic parameters in patients with type 2 diabetes
- โขCardiovascular safety assessment
Research Overview#
GUBamy (GUB014295) is in early clinical development with data limited to phase 1 SAD and MAD results communicated through company press releases. No peer-reviewed publications of clinical data exist. Despite the early stage, the phase 1 results are notable for the magnitude of weight loss observed, which attracted a $350 million upfront licensing deal from AbbVie.
The evidence level is classified as low based on phase 1 data only, communicated through company press releases without peer-reviewed publication, and tested in healthy volunteers rather than the target patient population.
Phase 1 SAD Study#
Study Design#
- Population: Healthy volunteers
- Design: Single ascending dose, placebo-controlled
- Doses: Multiple ascending doses up to approximately 6 mg subcutaneously
- Key assessments: Safety, pharmacokinetics, pharmacodynamics, body weight changes
Key Results#
Pharmacokinetics:
- Half-life of approximately 270 hours (11 days), confirming once-weekly dosing feasibility
- Dose-proportional pharmacokinetics across the dose range
- Predictable absorption from subcutaneous injection
Weight Effects:
- Dose-dependent body weight reduction observed even after a single dose
- The three highest dose groups (3.5-6.0 mg) showed approximately 3% weight loss over the 6-week observation period
- Placebo group showed approximately +1% weight change
- Weight loss from a single dose is consistent with the long 11-day half-life maintaining active drug levels for weeks
Safety:
- Well tolerated at all doses
- Adverse events were predominantly GI-related (nausea, consistent with amylin agonism)
- GI events were mild and transient
- No serious adverse events reported
Phase 1 MAD Study (Interim)#
Study Design#
- Population: Healthy volunteers
- Design: Multiple ascending dose, placebo-controlled
- Key dose reported: 2 mg subcutaneously once weekly
- Duration: Interim results at Day 43
Key Results#
| Endpoint | GUBamy 2 mg QW | Placebo |
|---|---|---|
| LS mean weight change at Day 43 | -7.77% | +1.99% |
| Difference vs placebo | ~-9.76% | -- |
The 7.77% mean weight loss at day 43 (approximately 6 weeks) is remarkable for several reasons:
- This is a phase 1 study in healthy volunteers (not obese patients)
- The duration was only 43 days
- For comparison, semaglutide 2.4 mg typically achieves ~5% weight loss at week 4-8 in obese patients
- The net difference from placebo (~9.76 percentage points) is large for this timeframe
Safety in MAD:
- Well tolerated, consistent with SAD data
- GI adverse events were predominantly mild
- No new safety signals compared to SAD
Context: DACRA Class Evidence#
GUBamy is not the only DACRA in development. The preclinical and clinical evidence for DACRAs provides additional context:
Preclinical DACRA Data#
- DACRAs (e.g., KBP-042, KBP-089) have shown weight loss and metabolic improvements in rodent models
- KBP-089 combined with liraglutide showed complementary effects on weight and metabolic parameters in preclinical studies
- DACRAs may provide metabolic benefits beyond what amylin-selective agents achieve
Related Clinical Programs#
- Cagrilintide (Novo Nordisk): Long-acting amylin analog (AMY-selective, not DACRA); phase 2 monotherapy showed modest weight loss; being developed primarily as combination with semaglutide (CagriSema)
- Petrelintide (Zealand Pharma): Long-acting amylin analog in phase 2 development
Evidence Quality Assessment#
| Criterion | Assessment | Details |
|---|---|---|
| Study phase | Phase 1 | SAD + MAD |
| Population | Healthy volunteers | Not target population |
| Sample size | Small | Phase 1 cohort sizes |
| Publication | Press releases only | No peer review |
| Duration | Short (6 weeks) | Long-term data absent |
| Comparator | Placebo only | No active comparator |
| Commercial validation | Strong | AbbVie $350M licensing |
Key Research Gaps#
-
Phase 2 dose-ranging: Identification of optimal dose(s) for obesity in the target patient population, with proper dose escalation and 26+ week treatment duration.
-
Combination with GLP-1 RAs: The primary commercial thesis is that GUBamy plus a GLP-1 RA will produce superior weight loss. This has not been tested clinically.
-
Peer-reviewed data: Publication of phase 1 results in a peer-reviewed journal is needed for independent evaluation.
-
Safety characterization: Longer-term safety in larger populations, particularly GI tolerability at optimal doses and cardiovascular safety.
-
Type 2 diabetes: Whether GUBamy provides glycemic benefits beyond weight loss in patients with type 2 diabetes.
Related Reading#
Frequently Asked Questions About GUBamy
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.